You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-TR-21-010: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 01-13-2021Open Date: 03-13-2021 Due Dates: Multiple Close Date: 01-13-2022

    A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underly multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecu ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PAR-20-098: Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)

    Release Date: 02-06-2020Open Date: 03-05-2020 Due Dates: Multiple Close Date: 01-06-2022

    Research Objectives Maximizing the therapeutic impact of somatic genome editing requires the development of safe and effective technologies to deliver genome editing machinery into all disease-relevant somatic cells and tissues. Therefore, the objective of this FOA is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with th ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PA-19-076 : Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44 Clinical Trial Not Allowed)

    Release Date: 11-26-2018Open Date: 03-05-2019 Due Dates: Multiple Close Date: 01-05-2022

    Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-DA-19-019 : HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44- Clinical Trial Optional)

    Release Date: 12-10-2018Open Date: 12-10-2018 Due Dates: Multiple Close Date: 09-08-2021

    The National Center for Advancing Translational Sciences (NCATS) will not accept primary assignment to applications proposing clinical trial(s) under this funding announcement. Please direct any questions to the NCATS scientific contact. Purpose More than 2 million individuals in the United States have an opioid use disorder (OUD), most starting with opioid analgesics prescribed to them or procu ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PA-18-708 : Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R43/R44 Clinical Trial Not Allowed)

    Release Date: 03-15-2018Open Date: 08-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background G-protein coupled receptor proteins (GPCRs) are membrane bound proteins that serve to modulate cellular activities. Many of the GPCRs have potential significance in healthy mental function and in mental disorders, including receptors for most neurotransmitters and neuropeptides. Drugs targeting GPCRs are currently used in the treatment of mental disorders such as schizophrenia, anxie ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PA-18-928 : Innovative Technologies for HIV Behavioral and Social Science Research (R43/R44 Clinical Trial Optional)

    Release Date: 09-19-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background Technology-enabled HIV research has emerged in the past decade as a dynamic field that offers potential to bring HIV prevention and treatment efforts to scale. Technological innovations can help to reach vulnerable and at-risk populations such as minorities, adolescents, older adults, and individuals from rural settings who have challenges accessing conventional prevention and treatmen ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PA-19-022: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R43/R44 Clinical Trial Not Allowed)

    Release Date: 10-10-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Purpose Digital dentistry uses advanced materials and powerful manufacturing technologies aided by 3D imaging and processing software algorithms to produce dental devices and perform complex dental procedures. This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delive ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. PAR-19-061 : Computational Genomics and Data Science Opportunities for Small Business (R43/R44 Clinical Trial Not Allowed)

    Release Date: 11-09-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background Since its inception the field of genomics has been grounded in computational approaches. All facets of genomic research, such as processing raw sequencing signals, assembling genomes, calling variants, deriving insight from population sequencing studies, and designing and studying the implementation of genomics in clinical settings, are dependent upon computational, analytical, statist ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PA-19-043: Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)

    Release Date: 10-31-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Section I. Funding Opportunity Description Background Sequencing studies, including the 1000 Genomes Project and many disease studies, have identified more than 100 million sites in the human genome that vary among people. However, it is likely that most of the variants do not contribute to differences in function, traits, disease risk, or clinical outcomes. Thus, methods to determine which ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PA-19-034 : Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)

    Release Date: 10-24-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background The human genome has revealed a great deal about the human proteome, though significant portions remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be discovered in the "Druggable Genome" (DG), which can be defined as a subset of the ~20,000 ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government